HLS Therapeutics Inc. publishes 2026 annual report

Reuters

Mar 13

<a href="https://laohu8.com/S/HLTRF">HLS Therapeutics Inc.</a> publishes 2026 annual report

HLS published its annual report outlining continued focus on specialty CNS and cardiovascular products, led by Clozaril in Canada and the U.S. and Vascepa in Canada. The company entered a new credit agreement in 2025 that replaced its prior facility and extended maturity to 2029, with total facilities of CAD 107 million. HLS also licensed Canadian rights to Nilemdo and Nexlizet from Esperion, paying an upfront fee of USD 1 million. Health Canada approved Nilemdo in November 2025, while Nexlizet received a Notice of Non-Compliance and is targeted for resolution in Q4 2026 ahead of a planned 2027 launch. In 2024, HLS sold its Xenpozyme royalty interest to DRI in a transaction valued at up to USD 45.75 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HLS Therapeutics Inc. published the original content used to generate this news brief on March 12, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2619591153"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619591153\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619591153?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 00:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619591153","market":"fut","top_or_hot":-1,"title":"HLS Therapeutics Inc. publishes 2026 annual report","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HLTRF\">HLS Therapeutics Inc.</a> publishes 2026 annual report\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HLS published its annual report outlining continued focus on specialty CNS and cardiovascular products, led by Clozaril in Canada and the U.S. and Vascepa in Canada. The company entered a new credit agreement in 2025 that replaced its prior facility and extended maturity to 2029, with total facilities of CAD 107 million. HLS also licensed Canadian rights to Nilemdo and Nexlizet from Esperion, paying an upfront fee of USD 1 million. Health Canada approved Nilemdo in November 2025, while Nexlizet received a Notice of Non-Compliance and is targeted for resolution in Q4 2026 ahead of a planned 2027 launch. In 2024, HLS sold its Xenpozyme royalty interest to DRI in a transaction valued at up to USD 45.75 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HLS <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. published the original content used to generate this news brief on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HLS Therapeutics Inc. publishes 2026 annual report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHLS Therapeutics Inc. publishes 2026 annual report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-13 00:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HLTRF\">HLS Therapeutics Inc.</a> publishes 2026 annual report\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HLS published its annual report outlining continued focus on specialty CNS and cardiovascular products, led by Clozaril in Canada and the U.S. and Vascepa in Canada. The company entered a new credit agreement in 2025 that replaced its prior facility and extended maturity to 2029, with total facilities of CAD 107 million. HLS also licensed Canadian rights to Nilemdo and Nexlizet from Esperion, paying an upfront fee of USD 1 million. Health Canada approved Nilemdo in November 2025, while Nexlizet received a Notice of Non-Compliance and is targeted for resolution in Q4 2026 ahead of a planned 2027 launch. In 2024, HLS sold its Xenpozyme royalty interest to DRI in a transaction valued at up to USD 45.75 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HLS <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. published the original content used to generate this news brief on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ESPR","symbol_name":"Esperion Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL1YbxNg:1","article_id":"2619591153","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619591153","pubTimestamp":1773332193,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HLS published its annual report outlining continued focus on specialty CNS and cardiovascular products, led by Clozaril in Canada and the U.S. and Vascepa in Canada. The company entered a new credit agreement in 2025 that replaced its prior facility and extended maturity to 2029, with total facilities of CAD 107 million. HLS also licensed Canadian rights to Nilemdo and Nexlizet from Esperion, paying an upfront fee of USD 1 million. Health Canada approved Nilemdo in November 2025, while Nexlizet received a Notice of Non-Compliance and is targeted for resolution in Q4 2026 ahead of a planned 2027 launch. In 2024, HLS sold its Xenpozyme royalty interest to DRI in a transaction valued at up to USD 45.75 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ESPR":"Esperion Therapeutics Inc.","BK4007":"制药"},"translate_title":"HLS Therapeutics Inc.发布2026年年度报告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESPR":0.9},"content_text":"HLS Therapeutics Inc. publishes 2026 annual report\n    \n\n        HLS published its annual report outlining continued focus on specialty CNS and cardiovascular products, led by Clozaril in Canada and the U.S. and Vascepa in Canada. The company entered a new credit agreement in 2025 that replaced its prior facility and extended maturity to 2029, with total facilities of CAD 107 million. HLS also licensed Canadian rights to Nilemdo and Nexlizet from Esperion, paying an upfront fee of USD 1 million. Health Canada approved Nilemdo in November 2025, while Nexlizet received a Notice of Non-Compliance and is targeted for resolution in Q4 2026 ahead of a planned 2027 launch. In 2024, HLS sold its Xenpozyme royalty interest to DRI in a transaction valued at up to USD 45.75 million.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HLS Therapeutics Inc. published the original content used to generate this news brief on March 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}